Primary familial brain calcification

Lore & Background

The disease was first noted by German pathologist Karl Theodor Fahr in 1930. It is also known as Fahr's disease and familial idiopathic basal ganglia calcification. Fewer than 20 families had been reported in the literature up to 1997. The condition usually manifests in the third to fifth decade of life but may appear in childhood or later. Symptoms include deterioration of motor functions and speech, seizures, involuntary movement, headaches, dementia, and vision impairment. Neuropsychiatric symptoms can range from mild concentration difficulty to psychosis and dementia.

Reader's Guide

Primary familial brain calcification is significant as a model for understanding the role of phosphate transport, blood-brain barrier integrity, and protein acetylation in neurological disease. The identification of multiple associated genes—SLC20A2 (phosphate transporter), PDGFB and PDGFRB (involved in pericyte recruitment and angiogenesis), XPR1 (phosphate exporter), MYORG, JAM2, and NAA60 (a Golgi-localized N-terminal acetyltransferase)—highlights the genetic heterogeneity of the condition. Diagnosis relies on CT scan evidence of bilateral basal ganglia calcification, progressive neurologic dysfunction, exclusion of other causes, and a compatible family history. There is no cure; treatment is symptomatic and often poorly responsive to levodopa. The prognosis is variable, with progressive deterioration generally leading to disability and death. The condition underscores the complexity of inherited neurological disorders and the importance of genetic testing in atypical presentations.

Did You Know?

• Brain calcifications may be absent in younger gene carriers, though no single age threshold is universally established.
• The most recently found associated gene is NAA60, which encodes a Golgi-localized N-terminal acetyltransferase.